An Update on Venous Thromboembolism in Cancer

Restricted access

Michael B. Streiff, MD, is Associate Professor of Medicine at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and the Chair of the NCCN Guidelines Panel on Venous Thromboembolic Disease.

The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.

  • 1.

    Khorana AA, Francis CW, Culakova E. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632634.

    • Search Google Scholar
    • Export Citation
  • 2.

    Tapson VF, Decousus H, Pini M. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the international medical prevention registry on venous thromboembolism. Chest 2007;132:936945.

    • Search Google Scholar
    • Export Citation
  • 3.

    Samama MM, Cohen AT, Darmon JY. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793800.

    • Search Google Scholar
    • Export Citation
  • 4.

    Leizorovicz A, Cohen AT, Turpie AG. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874879.

    • Search Google Scholar
    • Export Citation
  • 5.

    Cohen AT, Davidson BL, Gallus AS. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332:325329.

    • Search Google Scholar
    • Export Citation
  • 6.

    Bergqvist D, Agnelli G, Cohen AT. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975980.

    • Search Google Scholar
    • Export Citation
  • 7.

    Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg 1997;84:10991103.

    • Search Google Scholar
    • Export Citation
  • 8.

    Rasmussen MS, Jorgensen LN, Wille-Jorgensen P. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006;4:23842390.

    • Search Google Scholar
    • Export Citation
  • 9.

    Kakkar AK, Levine M, Pinedo HM. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 2003;8:381388.

  • 10.

    Agnelli G, Gussoni G, Bianchini C. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10:943949.

    • Search Google Scholar
    • Export Citation
  • 11.

    Agnelli G, George DJ, Kakkar AK. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366:601609.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 48 10 0
PDF Downloads 5 4 0
EPUB Downloads 0 0 0